Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients
- PMID: 19997980
- DOI: 10.1007/s11605-009-1115-0
Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients
Abstract
Objective: Pancreatic neuroendocrine cancer is a rare, indolent malignancy with no effective systemic therapy currently available. This population-based analysis evaluated the hypothesis that long-term survival benefit is greater with aggressive, rather than limited, surgical therapy.
Methods: Non-functional pancreatic neuroendocrine carcinoma (NF-pNEC) cases diagnosed from 1973 to 2004 were retrieved from the SEER database.
Results: A total of 2,158 patients with NF-pNEC were identified, representing 2% of all pancreatic malignancies. The annual incidence increased from 1.4 to 3.0 per million during the study period. On average, tumors measured 59 +/- 35 mm (median 50), and age at diagnosis was 59 +/- 15 years; 29% of patients were younger than 50. Nodal (44%) and systemic metastases (60%) were common. Overall the 5-, 10-, and 20-year survival rates were 33%, 17%, and 10%, respectively. Removal of the primary tumor significantly prolonged survival in the entire cohort (median 1.2 vs. 8.4 years; p < 0.001) and among those with metastases (median 1.0 vs. 4.8 years; p < 0.001). No survival difference was seen between enucleation and resection of the primary tumor (median 10.2 versus 9.2 years, p = 0.456).
Conclusion: This study suggests that surgical therapy improves survival among patients with localized, as well as metastatic, NF-pNEC. Enucleation may be oncologically equivalent to resection.
Similar articles
-
Surgical resection of the primary tumor leads to prolonged survival in metastatic pancreatic neuroendocrine carcinoma.World J Surg Oncol. 2019 Mar 21;17(1):54. doi: 10.1186/s12957-019-1597-5. World J Surg Oncol. 2019. PMID: 30898132 Free PMC article.
-
Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters.Surgery. 2016 Mar;159(3):862-71. doi: 10.1016/j.surg.2015.09.012. Surgery. 2016. PMID: 26602841
-
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9. doi: 10.1097/01.sla.0000128306.90650.aa. Ann Surg. 2004. PMID: 15166958 Free PMC article.
-
[Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].J Chir (Paris). 2005 May-Jun;142(3):132-49. doi: 10.1016/s0021-7697(05)80881-6. J Chir (Paris). 2005. PMID: 16142076 Review. French.
-
Pancreatectomy combined with superior mesenteric-portal vein resection: report of 32 cases.Hepatobiliary Pancreat Dis Int. 2005 Feb;4(1):130-4. Hepatobiliary Pancreat Dis Int. 2005. PMID: 15730937 Review.
Cited by
-
Contemporary Approaches to the Surgical Management of Pancreatic Neuroendocrine Tumors.Cancers (Basel). 2024 Apr 14;16(8):1501. doi: 10.3390/cancers16081501. Cancers (Basel). 2024. PMID: 38672582 Free PMC article. Review.
-
Development and validation of CT-based radiomics deep learning signatures to predict lymph node metastasis in non-functional pancreatic neuroendocrine tumors: a multicohort study.EClinicalMedicine. 2023 Oct 24;65:102269. doi: 10.1016/j.eclinm.2023.102269. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 38106556 Free PMC article.
-
Targeted IFNγ induction by a genetically engineered Salmonella typhimurium is the key to the liver metastasis inhibition in a mouse model of pancreatic neuroendocrine tumor.Front Med (Lausanne). 2023 Oct 31;10:1284120. doi: 10.3389/fmed.2023.1284120. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38020179 Free PMC article.
-
Optimal Lymphadenectomy in Patients with Well-Differentiated Nonfunctioning Pancreatic Neuroendocrine Neoplasms.J Clin Med. 2023 Oct 26;12(21):6778. doi: 10.3390/jcm12216778. J Clin Med. 2023. PMID: 37959242 Free PMC article.
-
Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis.Br J Cancer. 2023 Oct;129(8):1225-1237. doi: 10.1038/s41416-023-02389-6. Epub 2023 Aug 24. Br J Cancer. 2023. PMID: 37620408 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical